Arbutus Biopharma Corp. (NASDAQ: ABUS) shares jumped on Tuesday after the company reported positive data from its early stage clinical trial in patients with chronic hepatitis B virus (HBV) infection. As a result, one analyst took a liking to Arbutus and doubled its price target.
Specifically, the company reported positive follow-up data from Phase 1a/1b clinical trial in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound.
William Collier, president and CEO of Arbutus, noted that the new data from the study further demonstrated the robust activity of AB-729. He added that “these data keep us on track for achieving our goal of delivering a combination therapy that includes HBsAg reduction in chronic hepatitis B subjects.”
Wedbush weighed in on Arbutus, upgrading to an Outperform rating from Neutral and raising its price target to $4 from $2, implying an upside of 114% from the most recent closing price of $1.87.
The boutique brokerage firm detailed in its report:
We see the favorable safety profile, and overall magnitude and continued reduction of HBsAg levels through Week 12 at this dose as an indication that AB-729 is potentially competitive to other HBV RNAi agents in development. Furthermore, ABUS’ ultimate strategy may be differentiated by the company’s greater insight into durability of HBsAg knockdown from a single dose vs. competitors, which ultimately may allow for less frequent dosing within a defined combination treatment regimen. While we await progression of ABUS’s HBV preclinical pipeline into the clinic to gain further insight into a potential combination path, we believe ABUS shares are currently undervalued given the value attributed to similar competitor assets.
Arbutus Biopharma stock traded up about 30% to $2.45 on Tuesday, in a 52-week range of $0.82 to $3.66. The consensus price target is $9.32.
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
